It turned out, that the response to Ra-223-treatment could be best assessed with sodium fluoride-18 PET. The local reactions in the metastatic bone were seen in the PET studies.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Now, these findings have been characterized by other investigators, by introducing quantitative PET interpretation criteria . Our modified PERCIST criteria for response assessment in Ra-223-treatment are useful and simple, and can be used in the clinical routine. According to our experience Ra-223 is an essential part of treatment of metastatic castration resistant prostate cancer, if the disease is mainly in the skeleton.
Written by: Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland & MD Anderson Cancer Center, Houston, TX, USA
1. Kairemo K, Joensuu T. Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT. Diagnostics (Basel). 2015; 5: 413-427.
2. Joensuu T, Joensuu G, Kairemo K, Kiljunen T, Riener M, Aaltonen A, et al. Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation. Anticancer Res. 2016; 36: 6439-6447.
3. Rohren E, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, et al. Determination of Skeletal Tumor Burden of 18F-Fluoride PET/CT. J Nucl Med Mol 2015; 56: 1506-1512.
Read the abstract